New User Account Set Up

If you do not have an account with the Digest, please click on "Submit to the Digest." By logging in with your UCLA Login ID (formerly known as BOL Login), a new account will automatically be generated. If you experience any difficulties, please send an email to our help desk: drcsupport@mednet.ucla.edu.

Questions

If you have any questions or concerns, please email our help desk/support team: drcsupport@mednet.ucla.edu. We are more than happy to address any questions or concerns regarding the Weekly Message Digest system you may have.

How do I subscribe?

If you have a mednet email account (@mednet.ucla.edu), you should already be subscribed.

If you do not have a mednet email account or you are not receiving the Digest, please send an email to drcsupport@mednet.ucla.edu and we will add you to our list.

New CMV Vaccine Study in Adults with Both HIV and CMV Who Are on ART

Cytomegalovirus (CMV) infection is common in people living with HIV and may contribute to chronic inflammation, which is greater in people with HIV than in people without HIV. This study (study number A5355) is testing an investigational vaccine called Triplex® that targets CMV. It will see if vaccination with Triplex® is safe and reduces levels of inflammation measured in blood in adults living with HIV and CMV.

 

Basic eligibility criteria:

  • Age 18-65 years old
  • Living with HIV and positive for CMV (the study will do the test for CMV)
  • Undetectable on continuous HIV treatment (antiretroviral therapy) for at least 48 weeks
  • CD4 count above 250
  • Never had CD4 count below 100
  • No history of heart disease, stroke, or diabetes

For more information contact the UCLA study team at (310) 843-2015 or CAREoutreach@mednet.ucla.edu

Posting Information
This posting expired on September 04, 2022.
Posting Attachment: Download Attachment

Share this posting on social media!